Sonidegib as a Locally Advanced Basal Cell Carcinoma Therapy in Real-life Clinical Setting: A National Multicentre Study

Moreno-Arrones, O M; Béa-Ardebol, S; Mayo-Martinez, F; Pérez-Pastor, G; Torres-Navarro, I; Bonfill-Ortí, M; Deza-Vargas, L G; Ruiz-Salas, V; Masferrer, E; Feal, C; Turrión-Merino, L; Toll, A; Yébenes, M; Galiano-Mejías, S; Jaka, A; Ferrandiz-Pulido, C; Florez, A; Hernández-Hernández, N; Fernández-de-Misa, R; Rios-Buceta, L; Sanmartin, O

doi:10.1016/j.ad.2023.04.022

Cited by 4 publications

(4 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreno-Arrones O.M. et al found the onset of fewer AEs and a comparable efficacy when Sonidegib 200 mg was administered every other day [38]. Every one of the patients in this case series has been periodically assessed in a multidisciplinary setting formed by oncologists, maxillofacial surgeons, and dermatologists, among others, according to the most recent European consensus on BCC management guidelines [2].…”

Section: Discussionmentioning

confidence: 91%

See 1 more Smart Citation

Sonidegib in Locally Advanced Basal Cell Carcinoma: A Monocentric Retrospective Experience and a Review of Published Real-Life Data

Nazzaro

Benzecry

Mattioli

et al. 2023

Cancers

View full text Add to dashboard Cite

Basal cell carcinoma (BCC) represents the most common skin cancer and locally advanced BCC (laBCC) refers to an aggressive, large, infiltrative BCC that cannot be treated by surgery or radiotherapy. Sonidegib is a Hedghehog inhibitor (HHi) indicated for laBCC. This is a monocentric retrospective real-life study of laBCCs receiving Sonidegib treatment. Although Sonidegib is widely used, since its approval by Food and Drug Administration in 2015, only a limited number of real-life experiences have been reported. Eleven patients, including four patients diagnosed with Basal Cell Naevus syndrome, received treatment with Sonidegib for laBCCs. Seven (63.6%) patients experienced adverse events (AEs) but only three had to discontinue treatment and were therefore excluded from the following results. Four patients (50%) achieved complete clinical remission (CR); in all cases the remission was confirmed by biopsy. Partial response (PR) was found in three patients out of eight (37.5%). One patient out of eight (12.5%) showed a steady disease (SD). None of the patients showed signs of progression during treatment with HHi. Sonidegib showed the same efficacy in treating laBCCs as already seen in trials. All four patients suffering from Basal Cell Naevus syndrome achieved disease control by being treated with Sonidegib. Consequently, we strongly advise the joint management of laBCCs through a multidisciplinary team whenever feasible.

show abstract

Section: Discussionmentioning

confidence: 91%

“…These results reflect a somewhat minor efficacy of the treatment when compared to other real-life experiences. Probably, the inclusion of patients previously treated with Vismodegib (19.5%) is the explanation for the poorer trend of response to Sonidegib; of these patients, only 35.7% showed improvement with Sonidegib [38].…”

Section: Discussionmentioning

confidence: 99%

Sonidegib in Locally Advanced Basal Cell Carcinoma: A Monocentric Retrospective Experience and a Review of Published Real-Life Data

Nazzaro

Benzecry

Mattioli

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…In recent years, the treatment of advanced and metastatic cSCC and laBCC has undergone a significant improvement. 1 , 2 …”

Section: Discussionmentioning

confidence: 99%

Complete response of metastatic cutaneous squamous cell carcinoma and multiple locally advanced basal cell carcinomas with concomitant pembrolizumab and sonidegib therapy

González-Cruz,

Muñoz-Couselo,

Ortiz-Velez

et al. 2024

JAAD Case Reports

View full text Add to dashboard Cite

“…In den letzten Jahren hat sich die Behandlung von fortgeschrittenen und metastasierten kPEK und lfBZK signifikant verbessert [1, 2]. Die wenigen verfügbaren Fallberichte beschreiben Patienten sowohl mit fortgeschrittenem PEK als auch fortgeschrittenem BZK, die bei sequenzieller Behandlung mit Cemiplimab und Sonidegib eine verbesserte Ansprache zeigen [3, 4].…”

Section: Diskussionunclassified

Vollständiges Ansprechen eines metastasierten Plattenepithelkarzinoms der Haut und mehrerer multipler, lokal fortgeschrittener Basalzellkarzinome auf eine gleichzeitige Therapie mit Pembrolizumab und Sonidegib

González-Cruz,

Muñoz-Couselo,

Ortiz-Velez

et al. 2024

Kompass Dermatol

View full text Add to dashboard Cite

Sonidegib as a Locally Advanced Basal Cell Carcinoma Therapy in Real-life Clinical Setting: A National Multicentre Study

Cited by 4 publications

References 20 publications

Sonidegib in Locally Advanced Basal Cell Carcinoma: A Monocentric Retrospective Experience and a Review of Published Real-Life Data

Sonidegib in Locally Advanced Basal Cell Carcinoma: A Monocentric Retrospective Experience and a Review of Published Real-Life Data

Complete response of metastatic cutaneous squamous cell carcinoma and multiple locally advanced basal cell carcinomas with concomitant pembrolizumab and sonidegib therapy

Vollständiges Ansprechen eines metastasierten Plattenepithelkarzinoms der Haut und mehrerer multipler, lokal fortgeschrittener Basalzellkarzinome auf eine gleichzeitige Therapie mit Pembrolizumab und Sonidegib

Contact Info

Product

Resources

About